Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice

Blood

Volumn 126, Issue 15, 2015, Pages 1844-1855

  Arumugam, Paritha I ^a   Mullins, Eric S ^a   Shanmukhappa, Shiva Kumar ^a   Monia, Brett P ^b   Loberg, Anastacia ^a   Shaw, Maureen A ^a   Rizvi, Tilat ^a   Wansapura, Janaka ^a   Degen, Jay L ^a   Malik, Punam ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; INTERLEUKIN 6; PROTEINASE; PROTHROMBIN; THROMBIN; VASCULAR CELL ADHESION MOLECULE 1; FACTOR IIA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; CHRONIC INFLAMMATION; COHORT ANALYSIS; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GENETIC MANIPULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC ANEMIA; HEMOSTASIS; INFLAMMATORY INFILTRATE; KIDNEY DISEASE; LEUKOCYTOSIS; LIVER FUNCTION; MALE; MORTALITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTHROMBIN TIME; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFLAMMATION; SICKLE CELL ANEMIA; THROMBOCYTOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; COMPLICATION; ENZYME IMMUNOASSAY; GENE THERAPY; HYPERTENSION, PULMONARY; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; SURVIVAL RATE; VASCULAR DISEASES;

ANEMIA, SICKLE CELL; ANIMALS; BLOOD COAGULATION; CELLS, CULTURED; GENETIC THERAPY; HYPERTENSION, PULMONARY; IMMUNOENZYME TECHNIQUES; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, KNOCKOUT; OLIGORIBONUCLEOTIDES, ANTISENSE; PROTHROMBIN; SURVIVAL RATE; THROMBIN; VASCULAR DISEASES;

EID: 84943628761     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-625707     Document Type: Article

References (91)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994; 330(23):1639-1644.
2. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337(11): 762-769.
3. Brittenham GM, Schechter AN, Noguchi CT. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood. 1985;65(1): 183-189.
4. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106(3):411-420.
5. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389.
6. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340(13):1021-1030.
7. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm. Proc Natl Acad Sci USA. 2002;99(5):3047-3051.
8. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652-656.
9. Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood. 1996;88(6):1951-1953.
10. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014; 312(1):48-56.
11. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651.
12. Vichinsky EP, Haberkern CM, Neumayr L, et al; The Preoperative Transfusion in Sickle Cell Disease Study Group. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med. 1995;333(4): 206-213.
13. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998;101(9):1899-1904.
14. Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica. 2008;93(1):20-26.
15. Setty BN, Kulkarni S, Rao AK, Stuart MJ. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood. 2000;96(3): 1119-1124.
16. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood. 1996;88(5): 1873-1880.
17. Gavins FN, Russell J, Senchenkova EL, et al. Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S. Blood. 2011;117(15):4125-4133.
18. Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol. 2006;13(1):34-39.
19. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000; 96(7):2451-2459.
20. Blum A, Yeganeh S, Peleg A, et al. Endothelial function in patients with sickle cell anemia during and after sickle cell crises. J Thromb Thrombolysis. 2005;19(2):83-86.
21. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99(1):36-43.
22. Hofstra TC, Kalra VK, Meiselman HJ, Coates TD. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood. 1996;87(10):4440-4447.
23. Kato GJ, Martyr S, Blackwelder WC, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol. 2005; 130(6):943-953.
24. Kaul DK, Liu XD, Choong S, Belcher JD, Vercellotti GM, Hebbel RP. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2004;287(1):H293-H301.
25. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998;91(11):4216-4223.
26. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol. 2006;26(7):1626-1631.
27. Liesner R, Mackie I, Cookson J, et al. Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol. 1998;103(4): 1037-1044.
28. Setty BN, Chen D, Stuart MJ. Sickle red blood cells stimulate endothelial cell production of eicosanoids and diacylglycerol. J Lab Clin Med. 1996;128(3):313-321.
29. Setty BN, Stuart MJ. Vascular cell adhesion molecule-1 is involved in mediating hypoxiainduced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood. 1996;88(6):2311-2320.
30. Shet AS, Hoffmann TJ, Jirouskova M, et al. Morphological and functional platelet abnormalities in Berkeley sickle cell mice. Blood Cells Mol Dis. 2008;41(1):109-118.
31. Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood. 2004;104(3): 840-846.
32. Stuart MJ, Setty BN. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med. 2001; 20(1):27-46.
33. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med. 2001;137(6):398-407.
34. van Beers EJ, Schaap MC, Berckmans RJ, et al; CURAMA Study Group. Circulating erythrocytederived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009;94(11):1513-1519.
35. Zennadi R, Hines PC, De Castro LM, Cartron JP, Parise LV, Telen MJ. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood. 2004;104(12):3774-3781.
36. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(suppl 6):887S-968S.
37. Roach ES, Golomb MR, Adams R, et al; American Heart Association Stroke Council; Council on Cardiovascular Disease in the Young. Management of stroke in infants and children: A scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young [published correction appears in Stroke. 2009;40(1):e8-e10]. Stroke. 2008;39(9):2644-2691.
38. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet. 2005;37(4):435-440.
39. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med. 1972;287(17):846-849.
40. Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood. 2009;114(25):5117-5125.
41. Klings ES, Anton Bland D, Rosenman D, et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. Am J Hematol. 2008;83(7):547-553.
42. Chantrathammachart P, Mackman N, Sparkenbaugh E, et al. Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood. 2012;120(3):636-646.
43. Sparkenbaugh EM, Chantrathammachart P, Mickelson J, et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood. 2014;123(11): 1747-1756.
44. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program. 2007;2007:91-96.
45. Wolters HJ, ten Cate H, Thomas LL, et al. Lowintensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment? Br J Haematol. 1995;90(3):715-717.
46. Coughlin SR. Thrombin signalling and proteaseactivated receptors. Nature. 2000;407(6801): 258-264.
47. Chen D, Dorling A. Critical roles for thrombin in acute and chronic inflammation. J Thromb Haemost. 2009;7(suppl 1):122-126.
48. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev. 2004;84(2):579-621.
49. Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol. 2012;34(1):133-149.
50. Mullins ES, Kombrinck KW, Talmage KE, et al. Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood. 2009;113(3):696-704.
51. Pászty C. Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Curr Opin Hematol. 1997;4(2): 88-93.
52. Turpin B, Miller W, Rosenfeldt L, et al. Thrombin drives tumorigenesis in colitis-associated colon cancer. Cancer Res. 2014;74(11):3020-3030.
53. Perumbeti A, Higashimoto T, Urbinati F, et al. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood. 2009;114(6):1174-1185.
54. Sundaram N, Tailor A, Mendelsohn L, et al. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood. 2010;116(1):109-112.
55. Horowitz NA, Blevins EA, Miller WM, et al. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood. 2011;118(10):2889-2895.
56. Sun WY, Coleman MJ, Witte DP, Degen SJ. Rescue of prothrombin-deficiency by transgene expression in mice. Thromb Haemost. 2002; 88(6):984-991.
57. Guasch A, Navarrete J, Nass K, Zayas CF. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol. 2006;17(8):2228-2235.
58. Scheinman JI. Sickle cell disease and the kidney. Nat Clin Pract Nephrol. 2009;5(2):78-88.
59. Sharpe CC, Thein SL. Sickle cell nephropathy - A practical approach. Br J Haematol. 2011;155(3): 287-297.
60. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365(1): 44-53.
61. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J. 2012;39(1):112-118.
62. Hsu LL, Champion HC, Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood. 2007;109(7): 3088-3098.
63. Hoshikawa Y, Nana-Sinkam P, Moore MD, et al. Hypoxia induces different genes in the lungs of rats compared with mice. Physiol Genomics. 2003;12(3):209-219.
64. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med. 2000;162(4 Pt 1): 1577-1586.
65. Ozbek OY, Malbora B, Sen N, Yazici AC, Ozyurek E, Ozbek N. Airway hyperreactivity detected by methacholine challenge in children with sickle cell disease. Pediatr Pulmonol. 2007;42(12): 1187-1192.
66. Boyd JH, Moinuddin A, Strunk RC, DeBaun MR. Asthma and acute chest in sickle-cell disease. Pediatr Pulmonol. 2004;38(3):229-232.
67. Leong MA, Dampier C, Varlotta L, Allen JL. Airway hyperreactivity in children with sickle cell disease. J Pediatr. 1997;131(2):278-283.
68. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123(11): 4809-4820.
69. Salvaggio JE, Arnold CA, Banov CH. Long-term anti-coagulation in sickle-cell disease. A clinical study. N Engl J Med. 1963;269:182-186.
70. Büller HR, Bethune C, Bhanot S, et al; FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3): 232-240.
71. Dean NM, Bennett CF. Antisense oligonucleotidebased therapeutics for cancer. Oncogene. 2003; 22(56):9087-9096.
72. Frazier KS. Antisense oligonucleotide therapies: The promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol. 2015; 43(1):78-89.
73. van Tits LJ, van Heerde WL, Landburg PP, et al. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Commun. 2009; 390(1):161-164.
74. Flick MJ, Chauhan AK, Frederick M, et al. The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood. 2011; 117(23):6326-6337.
75. Flick MJ, Du X, Witte DP, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest. 2004;113(11):1596-1606.
76. Roszell NJ, Danton MJ, Jiang M, et al. Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice. Am J Hematol. 2007;82(12):1044-1048.
77. Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica. 2009;94(11):1481-1484.
78. Ataga KI, Brittain JE, Desai P, et al. Association of coagulation activation with clinical complications in sickle cell disease. PLoS One. 2012;7(1): e29786.
79. van Beers EJ, Spronk HM, Ten Cate H, et al; CURAMA study Group. No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. Haematologica. 2008;93(5):e42-e44.
80. Berger G, Azzam ZS, Hoffman R, Yigla M. Coagulation and anticoagulation in pulmonary arterial hypertension. Isr Med Assoc J. 2009; 11(6):376-379.
81. Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vasoocclusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood. 2008; 111(2):915-923.
82. Chaplin H Jr, Monroe MC, Malecek AC, Morgan LK, Michael J, Murphy WA. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J. 1989;66(9):574-584.
83. Chaplin H Jr, Alkjaersig N, Fletcher AP, Michael JM, Joist JH. Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost. 1980;43(3):218-221.
84. Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl. 1984;15:199-212.
85. Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr. 1983; 102(5):781-784.
86. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood. 2002;100(10):3790-3796.
87. Osamo NO, Photiades DP, Famodu AA. Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematol. 1981;66(2):102-107.
88. Semple MJ, Al-Hasani SF, Kioy P, Savidge GF. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost. 1984;51(3):303-306.
89. Zago MA, Costa FF, Ismael SJ, Tone LG, Bottura C. Treatment of sickle cell diseases with aspirin. Acta Haematol. 1984;72(1):61-64.
90. Schnog JB, van der Dijs FP, Fokkema MR, Muskiet FD, Muskiet FA. Folate status assessment and folic acid supplements in sickle cell disease. J Pediatr Hematol Oncol. 2001; 23(8):548.
91. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007;98(2): 392-396.